Abstract: The present disclosure aims to provide a cell culture container capable of easily producing large quantities of minute cellular structures. A cell culture container includes a plurality of first coated regions, on a culture surface of the cell culture container, coated by a temperature-responsive polymer or a temperature-responsive polymer composition. The surface zeta potential of the first coated regions is from 0 mV to 50 mV.

Abstract: A cardiac catheter inspection apparatus comprising: an acquiring section (31) which is configured to acquire a first waveform of heart beats during sinus rhythm, and an arrhythmia waveform during arrhythmia; a measuring section (31) which is configured to measure a second electrocardiogram; a first calculating section (32) which is configured to calculate correction coefficients for statistically matching the first electrocardiogram and the second electrocardiogram with each other; a waveform producing section (34) which is configured to produce a comparison waveform that functions as an object to be compared with a response waveform of pacing performed by a cardiac catheter; and a second calculating section (36) which is configured to calculate a matching rate of the response waveform and the comparison waveform.

Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.

Abstract: A monitoring apparatus includes a condition determining section which is configured to determine a condition of one of a heart, lungs, and blood vessels based on: a concentration of carbon dioxide in an expired gas which is measured by using a first sensor; and an oxygen transport parameter or a metabolic parameter which is measured by using a second sensor.

Abstract: A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.

Abstract: The present invention provides a valved stent that can provide a valve function without blocking a branch blood vessel, and also can provide a valve function with minimum covering of blood vessel tissue in a stent indwelling section. Specifically, a cylindrical stent body 4 is provided. A leaflet 5 that can open/close a blood vessel 2 in a blood flow direction is provided. The leaflet 5 is composed of connective tissue and protrudes radially inward from the stent body 4. An inside and an outside of the stent body 4 radially communicate with each other. The stent does not block a branch blood vessel 8. An area of the blood vessel covered with the stent is reduced.

Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.

Abstract: The present invention provides a connective tissue body formation substrate which can form a film-like connective tissue having a desired thickness and both surfaces in a desired surface condition without prolonging the time required for formation of the connective tissue. Specifically, two tissue formation surfaces 2a and 2b are faced with each other with a tissue formation space 3 being interposed therebetween. A slit 9 is formed in the tissue formation surface 2b so that the tissue formation space 3 communicates with an outside of the substrate. A connective tissue body formation substrate 1 is installed in an environment where a biological tissue material is present. A connective tissue intrudes into the tissue formation space 3 from the slit 9. Both surfaces of the film-like connective tissue are formed so as to match the substrate surface.

Abstract: A diagnosis assistance apparatus for assisting a diagnosis using schemas includes a storage section that stores a plurality of different schemas each configured by a figure representing a body region, an acquiring section that acquires results of a plurality of examinations that are performed on an examination target, a schema refining section that refines a schema of a body region related to a disease that is predicted from the acquired examination results, from the schemas step-by-step in accordance with progress of the examinations, and a displaying section that displays the schema refined by the schema refining section.

Abstract: A left atrial pressure measurement device includes: a measurement section that measures a first index value that indicates performance of a right ventricle, and a second index value that indicates performance of a left ventricle; and a calculation section that calculates a left atrial pressure using the first index value, the second index value, and a measured right atrial pressure.

Abstract: The present invention provides a stent that can obtain sufficient strength while an inner side of the stent is easily endothelialized and moreover, can prevent occlusion of a branch blood vessel. Specifically, a stent body capable of diameter expansion is provided. A tubular film 3 is held by the stent body. In the tubular film 3, a plurality of communication holes 4 communicating between an inside and an outside are formed. Band-shaped portions 7 and 8 are formed between the communication holes 4 adjacent to each other. A wide-width portion and a narrow portion are not generated in the band-shaped portions 7 and 8. Strength of a part of the band-shaped portions 7 and 8 is not lowered. Generation of the wide-width portion in the band-shaped portions 7 and 8 is prevented.

Abstract: A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.

Abstract: An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.

Abstract: A first blood vessel diameter and a second blood vessel diameter are measured using a first ultrasonic probe and a second ultrasonic probe that are provided close to a blood vessel of a subject so as to be situated at a given distance (Lp). Characteristic phases of a pulse wave are determined from the peak of a second-order differential value of the first blood vessel diameter and the peak of a second-order differential value of the second blood vessel diameter, and the difference (?t) in pulse wave transit time is calculated from the difference in timing between the characteristic phases to calculate pulse wave velocity (PWV). A given calculation process that uses the pulse wave velocity (PWV) and the measured blood vessel diameter as variables is performed to calculate blood pressure.

Abstract: A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof.

Abstract: The present invention provides a base material for forming a connective tissue structure which can accurately cut the connective tissue structure to a predetermined shape and a method for producing the connective tissue structure. A cutting-line forming groove (28) is formed in a surface of a base material (19). The base material (19) is placed under an environment in which a biological tissue material is present. A membranous connective tissue structure (20) is formed on the surface of the base material (19). At that time, a connective tissue (30) is made to invade into the cutting-line forming groove (28). A cutting line (31) for cutting is formed in the connective tissue structure (20). The connective tissue structure (20) is accurately cut along the cutting line (31) to a predetermined shape.

Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.

Abstract: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

Abstract: Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.